Trexquant Investment’s Haemonetics HAE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.3M | Buy |
218,010
+92,486
| +74% | +$6.02M | 0.09% | 304 |
|
|
2025
Q4 | $10.1M | Buy |
125,524
+15,879
| +14% | +$1.07M | 0.09% | 307 |
|
|
2025
Q3 | $5.34M | Buy |
109,645
+59,568
| +119% | +$3.69M | 0.06% | 527 |
|
|
2025
Q2 | $3.74M | Buy |
+50,077
| New | +$3.32M | 0.04% | 644 |
|
|
2023
Q3 | – | Sell |
-14,258
| Closed | -$1.21M | – | 1599 |
|
|
2023
Q2 | $1.21M | Sell |
14,258
-29,949
| -68% | -$2.53M | 0.03% | 692 |
|
|
2023
Q1 | $3.66M | Sell |
44,207
-20,894
| -32% | -$1.69M | 0.1% | 274 |
|
|
2022
Q4 | $5.12M | Buy |
65,101
+50,705
| +352% | +$4.08M | 0.15% | 186 |
|
|
2022
Q3 | $1.07M | Sell |
14,396
-112,043
| -89% | -$8.04M | 0.04% | 509 |
|
|
2022
Q2 | $8.24M | Buy |
126,439
+123,026
| +3,605% | +$7.28M | 0.37% | 54 |
|
|
2022
Q1 | $216K | Sell |
3,413
-4,456
| -57% | -$242K | 0.01% | 1163 |
|
|
2021
Q4 | $417K | Buy |
+7,869
| New | +$479K | 0.03% | 738 |
|
|
2021
Q1 | – | Sell |
-2,928
| Closed | -$348K | – | 1252 |
|
|
2020
Q4 | $348K | Sell |
2,928
-1,929
| -40% | -$208K | 0.04% | 609 |
|
|
2020
Q3 | $424K | Buy |
+4,857
| New | +$424K | 0.03% | 765 |
|
|
2020
Q1 | – | Sell |
-6,417
| Closed | -$737K | – | 1235 |
|
|
2019
Q4 | $737K | Sell |
6,417
-1,109
| -15% | -$134K | 0.04% | 444 |
|
|
2019
Q3 | $949K | Buy |
+7,526
| New | +$955K | 0.08% | 298 |
|
|
2019
Q2 | – | Sell |
-12,093
| Closed | -$1.06M | – | 932 |
|
|
2019
Q1 | $1.06M | Buy |
+12,093
| New | +$1.1M | 0.08% | 385 |
|
|
2018
Q4 | – | Sell |
-2,080
| Closed | -$238K | – | 1132 |
|
|
2018
Q3 | $238K | Sell |
2,080
-34,285
| -94% | -$3.55M | 0.02% | 762 |
|
|
2018
Q2 | $3.26M | Buy |
36,365
+17,756
| +95% | +$1.5M | 0.23% | 150 |
|
|
2018
Q1 | $1.36M | Buy |
+18,609
| New | +$1.28M | 0.09% | 335 |
|
|
2017
Q4 | – | Sell |
-10,302
| Closed | -$462K | – | 1119 |
|
|
2017
Q3 | $462K | Buy |
+10,302
| New | +$428K | 0.12% | 304 |
|
|
2017
Q1 | – | Sell |
-6,682
| Closed | -$269K | – | 1172 |
|
|
2016
Q4 | $269K | Buy |
+6,682
| New | +$252K | 0.04% | 693 |
|
|
2016
Q3 | – | Sell |
-12,445
| Closed | -$361K | – | 826 |
|
|
2016
Q2 | $361K | Buy |
+12,445
| New | +$376K | 0.05% | 598 |
|
|
2015
Q4 | – | Sell |
-12,100
| Closed | -$391K | – | 1121 |
|
|
2015
Q3 | $391K | Buy |
+12,100
| New | +$455K | 0.03% | 808 |
|
Other funds holding HAE
VPM
VCM
RRAM
Trexquant Investment's HAE Position: Q1 2026 in Review
Trexquant Investment increased its Haemonetics (HAE) stake by 74% in Q1 2026, buying an estimated $6.02M and bringing the position to 218,010 shares worth $12.3M. The position accounts for 0.09% of the portfolio, ranked #304.
Trexquant Investment first reported a position in HAE in Q3 2015 and has held it in 23 quarters since. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.
- Trexquant Investment held 218,010 shares of Haemonetics worth $12.3M as of Q1 2026.
- Trexquant Investment bought 92,486 Haemonetics shares in Q1 2026, an estimated $6.02M.
- Haemonetics made up 0.09% of Trexquant Investment's portfolio in Q1 2026, its #304 holding.
- Trexquant Investment first reported a position in Haemonetics in Q3 2015 and has held it in 23 quarters since.
- 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.
Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.